Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis

E Vercauteren, A Gils… - Seminars in thrombosis …, 2013 - thieme-connect.com
Thrombin activatable fibrinolysis inhibitor (TAFI) was discovered two decades ago
consequent to the identification of an unstable carboxypeptidase (CPU) formed upon …

Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model

E Vercauteren, J Emmerechts… - Blood, The Journal …, 2011 - ashpublications.org
The enhancement of fibrinolysis constitutes a promising approach to treat thrombotic
diseases. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) attenuates fibrinolysis …

Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

N Mishra, E Vercauteren, J Develter… - Thrombosis and …, 2011 - thieme-connect.com
Thrombin activatable fibrinolysis inhibitor (TAFI) forms a molecular link between coagulation
and fibrinolysis and is a putative target to develop profibrinolytic drugs. Out of a panel of …

Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue

L Johnston, M Power, P Sloan, A Long… - Journal of Clinical …, 2018 - jcp.bmj.com
Aims Understanding the molecular mechanisms of underlying disease has led to a
movement away from the one-drug-fits-all paradigm towards treatment tailored to the genetic …

[HTML][HTML] The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is …

E Vercauteren, M Peeters, MF Hoylaerts… - Journal of Thrombosis …, 2012 - Elsevier
Background: Mice with single gene deficiency of thrombin‐activatable fibrinolysis inhibitor
(TAFI) or plasminogen activator inhibitor‐1 (PAI‐1) have an enhanced fibrinolytic capacity …

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

E Vercauteren, NJ Mutch, PJ Declerck… - Journal of Thrombosis …, 2013 - jthjournal.org
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is formed upon activation of TAFI
by thrombin, either alone or in complex with thrombomodulin (T/TM complex), and by …

Is there any need for a TAFI (a) inhibitor as thrombolytic drug?

E Vercauteren, A Gils - Thrombosis research, 2012 - thrombosisresearch.com
Worldwide, the most frequently used thrombolytics to treat acute arterial thrombosis are
streptokinase and genetically modified versions of tissue-type plasminogen activator (tPA) ie …

[HTML][HTML] Ultra-rapid, sensitive, and fully automated extended RAS testing for metastatic colorectal cancer–evaluation of an NRAS/BRAF/EGFR492 module

E Vercauteren, E Bellon, K Vermeiren… - Annals of …, 2016 - annalsofoncology.org
Background Extended RAS testing in codons 12, 13, 59, 61, 117, and 146 in exons 2, 3, and
4 of the KRAS and NRAS genes is now mandatory before anti-EGFR therapy in metastatic …

[PDF][PDF] Rapid EGFR Mutation Testing in Lung Cancer Samples: The IdyllaTM System

L Bollen, M Van der Auwera, G Vandercruyssen… - biocartis.com
After insertion of a single FFPE slice into the cartridge, the complete process of sample
liquefaction, nucleic acid preparation, real-time PCR, data analysis and reporting is fully …

[CITATION][C] Hyperfibrinolysis through gene deletion or pharmacological inhibition of TAFI in mice.

E Vercauteren - 2012